Table 1. BRASS Cohort Characteristics

of DMARDS 445 patients (87%)
Methotrexate 230 patients (45%) TNF-α inhibitors 179 patients (35%)

57.8±13.9 years
ation of Disease 14.5±12.2 years
S28-CRP score 4.2±1.6
HAQ score 0.66±0.54

nder 83% female

mber of Subjects 511 patients

2. Clinical Evaluation by Grade of Dyspnea